The Enterprise Value as of September 2024 (TTM) for BioAtla, Inc. (BCAB) is 20.72M

According to BioAtla, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 20.72M. This represents a change of 100.06% compared to the average of 10.36M of the last 4 quarters.

BioAtla, Inc. (BCAB) Historical Enterprise Value (quarterly & annually)

How has BCAB Enterprise Value performed in the past?

The mean historical Enterprise Value of BioAtla, Inc. over the last ten years is 532.74M. The current 20.72M Enterprise Value has changed 288.95% with respect to the historical average. Over the past ten years (40 quarters), BCAB's Enterprise Value was at its highest in in the March 2021 quarter at 1.49B. The Enterprise Value was at its lowest in in the June 2022 quarter at -90936068.05.

BioAtla, Inc. (BCAB) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of BioAtla, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

BioAtla, Inc. (BCAB) Average Enterprise Value

How has BCAB Enterprise Value performed in the past?

The current Enterprise Value of BioAtla, Inc. (BCAB) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

BioAtla, Inc. (BCAB) Enterprise Value vs. Peers

How is BCAB’s Enterprise Value compared to its peers?

BioAtla, Inc.’s Enterprise Value is less than PMV Pharmaceuticals, Inc. (41.69M), less than C4 Therapeutics, Inc. (438.02M), less than Nautilus Biotechnology, Inc. (379.56M), less than Century Therapeutics, Inc. (150.46M), less than Passage Bio, Inc. (47.27M), less than Ikena Oncology, Inc. (47.83M), less than Olema Pharmaceuticals, Inc. (677.42M), less than Aerovate Therapeutics, Inc. (25.04M), less than Adagene Inc. (46.91M), less than Acrivon Therapeutics, Inc. Common Stock (217.30M), less than Rezolute, Inc. (282.50M), greater than AN2 Therapeutics, Inc. (4.27M), less than Gracell Biotechnologies Inc. (5.46B), less than Theseus Pharmaceuticals, Inc. (138.26M), less than Monte Rosa Therapeutics, Inc. (284.11M), less than Design Therapeutics, Inc. (275.21M), less than Erasca, Inc. (665.11M), less than Foghorn Therapeutics Inc. (418.19M), less than Shattuck Labs, Inc. (118.29M), less than Kymera Therapeutics, Inc. (3.13B), less than Nurix Therapeutics, Inc. (1.57B),

Build a custom stock screener for BioAtla, Inc. (BCAB) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioAtla, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BioAtla, Inc. (BCAB) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BioAtla, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.